

seizure free since December 25, 2020. They take anti-seizure medication with the dosage and frequency remaining the same since 2020. Their physician states that they are supportive of Jeffrey Muller receiving an exemption.

*Francis Palumbo*

Francis Palumbo is a 43-year-old class 10 license holder in Rhode Island. They have a history of epilepsy and have been seizure free since February 15, 2024. They take anti-seizure medication with the dosage and frequency remaining the same since February 15, 2024. Their physician states that they are supportive of Francis Palumbo receiving an exemption.

*William Roberson*

William Roberson is a 35-year-old class DV license holder in Alabama. They have a history of epilepsy and have been seizure free since August 24, 2023. They take anti-seizure medication with the dosage and frequency remaining the same since August 2023. Their physician states that they are supportive of William Roberson receiving an exemption.

*Ernest Sang*

Ernest Sang is a 55-year-old class A CDL holder in North Carolina. They have a history of provoked single seizure and have been seizure free since August 8, 2020. They take anti-seizure medication with the dosage and frequency remaining the same since 2020. Their physician states that they are supportive of Ernest Sang receiving an exemption.

*Robert Schauer*

Robert Schauer is a 40-year-old class A CDL holder in Iowa. They have a history of epilepsy and have been seizure free since August 2012. They take anti-seizure medication with the dosage and frequency remaining the same since April 2017. Their physician states that they are supportive of Robert Schauer receiving an exemption.

*Corbin Shoppell*

Corbin Shoppell is a 24-year-old regular operator license holder in Indiana. They have a history of seizure disorder and have been seizure free since May 2021. They take anti-seizure medication with the dosage and frequency remaining the same since 2021. Their physician states that they are supportive of Corbin Shoppell receiving an exemption.

*Marc Stoltenberg*

Marc Stoltenberg is a 27-year-old class D license holder in Minnesota. They

have a history of a provoked seizure and have been seizure free since September 17, 2022. They take anti-seizure medication with the dosage and frequency remaining the same since 2022. Their physician states that they are supportive of Marc Stoltenberg receiving an exemption.

*John Trout*

John Trout is a 19-year-old class C license holder in Maryland. They have a history of generalized tonic clonic epilepsy and have been seizure free since February 2020. They take anti-seizure medication with the dosage and frequency remaining the same since June 2020. Their physician states that they are supportive of John Trout receiving an exemption.

*Austin Wickizer*

Austin Wickizer is a 19-year-old class D license holder in Virginia. They have a history of epilepsy and have been seizure free since November 2018. They take anti-seizure medication with the dosage and frequency remaining the same since October 2018. Their physician states that they are supportive of Austin Wickizer receiving an exemption.

*Joshua Willits*

Joshua Willits is a 31-year-old class C license holder in Pennsylvania. They have a history of generalized epilepsy and have been seizure free since February 7, 2022. They take anti-seizure medication with the dosage and frequency remaining the same since February 11, 2022. Their physician states that they are supportive of Joshua Willits receiving an exemption.

*Alan Wilson*

Alan Wilson is a 63-year-old class A CDL holder in New Hampshire. They have a history of an unprovoked seizure and have been seizure free since June 1, 2024. They take anti-seizure medication with the dosage and frequency remaining the same since July 8, 2024. Their physician states that they are supportive of Alan Wilson receiving an exemption.

**V. Request for Comments**

In accordance with 49 U.S.C. 31136(e) and 31315(b), FMCSA requests public comment from all interested persons on the exemption petitions described in this notice. We will consider all comments received before the close of business on the closing date indicated under the **DATES** section of the notice. Jarrett Benjamin (NY)  
Donald Buck (OH)  
Christopher Brandt (NY)

Wyatt Chisamore (VT)  
Teagan Clark (NC)  
Derrick Cudd (IA)  
Zane DeGross (UT)  
Charles Elliott (MO)  
Jonathan Flight (NE)  
Jason Griese (ND)  
Jacob Griffin (WI)  
Andrew Harenchar (OH)  
Darren Holthaus (KS)  
John Honey (MT)  
Aaron Johnson (NC)  
James Klucas (KA)  
Kenneth Lone (UT)  
Ashley Marshall (ME)  
Nathan Moe (MN)  
Aaron Moore (RI)  
Dale Mosely (IN)  
Jeffrey Muller (PA)  
Francis Palumbo (RI)  
William Roberson (AL)  
Ernest Sang (NC)  
Robert Schauer (IA)  
Corbin Shoppell (IN)  
Marc Stoltenberg (MN)  
John Trout (MD)  
Austin Wickizer (VA)  
Joshua Willits (PA)  
Alan Wilson (NH)

**Larry W. Minor,**

*Associate Administrator for Policy.*

[FR Doc. 2025–05252 Filed 3–26–25; 8:45 am]

**BILLING CODE 4910-EX-P**

**DEPARTMENT OF TRANSPORTATION**

**Federal Motor Carrier Safety Administration**

[Docket No. FMCSA–2014–0215; FMCSA–2015–0323; FMCSA–2016–0008; FMCSA–2018–0028; FMCSA–2018–0053; FMCSA–2018–0056; FMCSA–2020–0050; FMCSA–2022–0045; FMCSA–2022–0046]

**Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders; Correction**

**AGENCY:** Federal Motor Carrier Safety Administration (FMCSA), Department of Transportation (DOT).

**ACTION:** Notice of renewal of exemptions; request for comments; correction.

**SUMMARY:** FMCSA corrects its January 6, 2025, notice requesting comments for 19 individuals to renew exemptions from the Agency's requirement in the Federal Motor Carrier Safety Regulations (FMCSRs) that interstate commercial motor vehicle (CMV) drivers have no established medical history or clinical diagnosis of epilepsy or any other condition which is likely to cause loss of consciousness or any loss of ability to control a CMV. An individual's name was misspelled, and this notice corrects that error.

**DATES:** This correction is effective March 27, 2025. Comments on the notice must be received on or before March 5, 2025.

**FOR FURTHER INFORMATION CONTACT:** Ms. Christine A. Hydock, Chief, Medical Programs Division, FMCSA, DOT, 1200 New Jersey Avenue SE, Room W64-224, Washington, DC 20590-0001; (202) 366-4001; [fmcsamedical@dot.gov](mailto:fmcsamedical@dot.gov). Office hours are from 8:30 a.m. to 5 p.m. ET Monday through Friday, except Federal holidays. If you have questions regarding viewing materials in the docket, contact Dockets Operations, (202) 366-9826.

**SUPPLEMENTARY INFORMATION:** On January 6, 2025 (90 FR 718), FMCSA published a notice of renewal of exemption in which the Agency announced its decision to renew exemptions for 19 individuals from the requirement that interstate CMV drivers have “no established medical history or clinical diagnosis of epilepsy or any other condition which is likely to cause loss of consciousness or any loss of ability to control a CMV.” The exemptions enable these individuals who have had one or more seizures and are taking anti-seizure medication to operate CMVs in interstate commerce, provided certain conditions are satisfied. The name of an individual listed in the notice is misspelled. Through this notice, FMCSA corrects the error in the spelling of their name.

In FR Doc. 2024-31759 appearing on page 718 in the **Federal Register** of January 6, 2025, the following correction is made:

1. On page 719, in the second column, the individual’s name, “Kieth Maat (KS)” is corrected to read “Keith Maat (KS).”

Issued under authority delegated in 49 CFR 1.87.

Larry W. Minor,

Associate Administrator for Policy.

[FR Doc. 2025-05256 Filed 3-26-25; 8:45 am]

BILLING CODE 4910-EX-P

## DEPARTMENT OF TRANSPORTATION

### Federal Motor Carrier Safety Administration

[Docket No. FMCSA-2025-0010]

#### Qualification of Drivers; Exemption Applications; Epilepsy and Seizure Disorders

**AGENCY:** Federal Motor Carrier Safety Administration (FMCSA), Department of Transportation (DOT).

**ACTION:** Notice of applications for exemption; request for comments.

**SUMMARY:** FMCSA announces receipt of applications from 11 individuals for an exemption from the prohibition in the Federal Motor Carrier Safety Regulations (FMCSRs) against persons with a clinical diagnosis of epilepsy or any other condition that is likely to cause a loss of consciousness or any loss of ability to control a commercial motor vehicle (CMV) to drive in interstate commerce. If granted, the exemptions would enable these individuals who have had one or more seizures and are taking anti-seizure medication to operate CMVs in interstate commerce.

**DATES:** Comments must be received on or before April 28, 2025.

**ADDRESSES:** You may submit comments identified by the Federal Docket Management System Docket No. FMCSA-2025-0010 using any of the following methods:

- *Federal eRulemaking Portal:* Go to [www.regulations.gov/](http://www.regulations.gov/), insert the docket number (FMCSA-2025-0010) in the keyword box and click “Search.” Next, choose the only notice listed, and click on the “Comment” button. Follow the online instructions for submitting comments.
- *Mail:* Dockets Operations; U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor, Washington, DC 20590-0001.
- *Hand Delivery:* West Building Ground Floor, 1200 New Jersey Avenue SE, Washington, DC 20590-0001 between 9 a.m. and 5 p.m. ET Monday through Friday, except Federal holidays.
- *Fax:* (202) 493-2251.

To avoid duplication, please use only one of these four methods. See the “Public Participation” portion of the **SUPPLEMENTARY INFORMATION** section for instructions on submitting comments.

**FOR FURTHER INFORMATION CONTACT:** Ms. Christine A. Hydock, Chief, Medical Programs Division, FMCSA, DOT, 1200 New Jersey Avenue SE, Washington, DC 20590-0001, (202) 366-4001, [fmcsamedical@dot.gov](mailto:fmcsamedical@dot.gov). Office hours are 8:30 a.m. to 5 p.m. ET Monday through Friday, except Federal holidays. If you have questions regarding viewing or submitting material to the docket, contact Dockets Operations, (202) 366-9826.

#### SUPPLEMENTARY INFORMATION:

##### I. Public Participation

###### A. Submitting Comments

If you submit a comment, please include the docket number for this notice (Docket No. FMCSA-2025-0010),

indicate the specific section of this document to which each comment applies, and provide a reason for each suggestion or recommendation. You may submit your comments and material online or by fax, mail, or hand delivery, but please use only one of these means. FMCSA recommends that you include your name and a mailing address, an email address, or a phone number in the body of your document so that FMCSA can contact you if there are questions regarding your submission.

To submit your comment online, go to <https://www.regulations.gov/docket/FMCSA-2025-0010>. Next, choose the only notice listed, click the “Comment” button, and type your comment into the text box on the following screen. Choose whether you are submitting your comment as an individual or on behalf of a third party and then submit.

If you submit your comments by mail or hand delivery, submit them in an unbound format, no larger than 8½ by 11 inches, suitable for copying and electronic filing. FMCSA will consider all comments and material received during the comment period.

##### B. Confidential Business Information (CBI)

CBI is commercial or financial information that is both customarily and actually treated as private by its owner. Under the Freedom of Information Act (5 U.S.C. 552), CBI is exempt from public disclosure. If your comments responsive to the notice contain commercial or financial information that is customarily treated as private, that you actually treat as private, and that is relevant or responsive to the notice, it is important that you clearly designate the submitted comments as CBI. Please mark each page of your submission that constitutes CBI as “PROPIN” to indicate it contains proprietary information. FMCSA will treat such marked submissions as confidential under the Freedom of Information Act, and they will not be placed in the public docket of the notice. Submissions containing CBI should be sent to Brian Dahlin, Chief, Regulatory Evaluation Division, Office of Policy, FMCSA, 1200 New Jersey Avenue SE, Washington, DC 20590-0001 or via email at [brian.g.dahlin@dot.gov](mailto:brian.g.dahlin@dot.gov). At this time, you need not send a duplicate hardcopy of your electronic CBI submissions to FMCSA headquarters. Any comments FMCSA receives not specifically designated as CBI will be placed in the public docket for this notice.